Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Female
Fluorescent Antibody Technique
HLA-DR Antigens
/ immunology
Humans
Kaplan-Meier Estimate
Macrophages
/ immunology
Male
Melanoma
/ blood
Middle Aged
Neoplasm Staging
Retrospective Studies
Risk Assessment
/ methods
Skin
/ immunology
T-Lymphocytes, Cytotoxic
/ immunology
Transcriptome
/ immunology
Tumor Microenvironment
/ genetics
Young Adult
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
22
07
2019
revised:
25
11
2019
accepted:
10
01
2020
pubmed:
18
1
2020
medline:
2
10
2020
entrez:
18
1
2020
Statut:
ppublish
Résumé
Patients with resected stage II-III melanoma have approximately a 35% chance of death from their disease. A deeper understanding of the tumor immune microenvironment (TIME) is required to stratify patients and identify factors leading to therapy resistance. We previously identified that the melanoma immune profile (MIP), an IFN-based gene signature, and the ratio of CD8
Identifiants
pubmed: 31948941
pii: 0008-5472.CAN-19-2039
doi: 10.1158/0008-5472.CAN-19-2039
pmc: PMC7112471
mid: NIHMS1550322
doi:
Substances chimiques
Biomarkers, Tumor
0
HLA-DR Antigens
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1078-1087Subventions
Organisme : NCI NIH HHS
ID : U54 CA193313
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007367
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001874
Pays : United States
Organisme : NCI NIH HHS
ID : UH2 CA218149
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Pathology. 2016 Feb;48(2):177-87
pubmed: 27020390
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Expert Rev Mol Diagn. 2014 Jul;14(6):643-6
pubmed: 24914691
Clin Cancer Res. 2015 Jan 1;21(1):175-83
pubmed: 25564571
Cancer Immunol Res. 2014 Jul;2(7):598-605
pubmed: 24990240
J Invest Dermatol. 2014 Aug;134(8):2202-2211
pubmed: 24522433
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
J Oncol. 2019 Apr 28;2019:5269062
pubmed: 31182961
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Nat Biotechnol. 2008 Mar;26(3):317-25
pubmed: 18278033
J Clin Oncol. 1999 Sep;17(9):2745-51
pubmed: 10561349
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Clin Cancer Res. 2019 Apr 15;25(8):2494-2502
pubmed: 30647081
Cancer. 1996 Apr 1;77(7):1303-10
pubmed: 8608507
JAMA Dermatol. 2019 Jun 1;155(6):688-693
pubmed: 31042258
Nat Commun. 2017 Apr 27;8:15095
pubmed: 28447602
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
Am J Clin Pathol. 2001 Jun;115(6):856-60
pubmed: 11392882
Sci Transl Med. 2015 Mar 4;7(277):277ra30
pubmed: 25739764
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Immunol Res. 2018 Apr;6(4):481-493
pubmed: 29467127
Trends Immunol. 2015 Apr;36(4):229-39
pubmed: 25770924
J Leukoc Biol. 2009 Nov;86(5):1065-73
pubmed: 19741157
Mod Pathol. 2015 Jun;28(6):766-77
pubmed: 25720324
J Transl Med. 2013 Oct 02;11:242
pubmed: 24088396
Neoplasia. 2019 Mar;21(3):282-293
pubmed: 30743162
Cancer Sci. 2014 Jan;105(1):1-8
pubmed: 24168081
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
BMC Cancer. 2010 Mar 25;10:112
pubmed: 20338029
J Clin Oncol. 2012 Jul 20;30(21):2678-83
pubmed: 22711850
Melanoma Res. 2018 Oct;28(5):478-482
pubmed: 30004988
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Med Res Rev. 2017 Jan;37(1):98-148
pubmed: 27569556
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119